Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Avrobio Plunges on Mixed Data from Fabry Disease Gene Therapy Trial

Shares of Cambridge, Mass.-based Avrobio plunged more than 50 percent after the company provided an updated look at a gene therapy for Fabry disease that showed promise for the treatment, but also raised some concern for investors.

Read More »

Rare manufacturing glitch raises concern over CAR-T therapies: study

A single leukemia cell inadvertently got mixed in with a batch of a patient’s immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported.

Read More »

Roche to acquire immuno-oncology company Tusk Therapeutics

Switzerland’s Roche is buying UK-based Tusk Therapeutics in a deal that could hit EUR 655 million.

Read More »

Adults need a regular bedtime, too

Adults who have a regular bedtime are likely to weigh less than those who do not, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study.

Read More »

Could Immunotherapy Replace Antiretrovirals in HIV Treatment?

An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. A study shows the two-drug combination is capable of suppressing HIV for months at a time.

Read More »

Fund gives J&J, Oxford experts $19 million to fight deadly viruses

A global coalition set up to fight emerging epidemics will give $19 million to drugmaker Johnson & Johnson’s vaccine unit and Oxford University experts to work on immunizations against three major diseases.

Read More »

GSK vaccine success a milestone in TB, but room for improvement

An experimental GlaxoSmithKline vaccine could prevent tuberculosis developing in half of those who receive it, making the vaccine potentially the first new shot against the global killer in a century.

Read More »

Roche’s Tecentriq, trailing rival drugs, lifts lung cancer survival

A drug cocktail with Roche’s Tecentriq added two months to small-cell lung cancer patients’ lives, according to a study, aiding the Swiss group’s bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.

Read More »

AstraZeneca buoyed as Imfinzi cuts lung cancer deaths by a third

AstraZeneca’s immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.

Read More »

Fewer U.S. adults getting unnecessary knee surgery

So-called arthroscopic knee surgery is becoming a less common treatment for adults with torn cartilage or painful arthritis as a growing body of evidence shows little benefit from these operations, a U.S. study suggests.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!

Subscribe

Ad Right Bottom